Annual D&A
$26.01 M
+$7.79 M+42.73%
December 31, 2023
Summary
- As of February 7, 2025, RARE annual depreciation & amortization is $26.01 million, with the most recent change of +$7.79 million (+42.73%) on December 31, 2023.
- During the last 3 years, RARE annual D&A has risen by +$13.74 million (+112.10%).
- RARE annual D&A is now at all-time high.
Performance
RARE Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
Quarterly D&A
$8.76 M
-$105.00 K-1.18%
September 30, 2024
Summary
- As of February 7, 2025, RARE quarterly depreciation & amortization is $8.76 million, with the most recent change of -$105.00 thousand (-1.18%) on September 30, 2024.
- Over the past year, RARE quarterly D&A has increased by +$1.57 million (+21.78%).
- RARE quarterly D&A is now -1.18% below its all-time high of $8.86 million, reached on June 30, 2024.
Performance
RARE Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
TTM D&A
$34.68 M
+$1.57 M+4.73%
September 30, 2024
Summary
- As of February 7, 2025, RARE TTM depreciation & amortization is $34.68 million, with the most recent change of +$1.57 million (+4.73%) on September 30, 2024.
- Over the past year, RARE TTM D&A has increased by +$11.94 million (+52.48%).
- RARE TTM D&A is now at all-time high.
Performance
RARE TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
RARE Depreciation And Amortization Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +42.7% | +21.8% | +52.5% |
| 3 y3 years | +112.1% | +172.2% | +170.2% |
| 5 y5 years | +33.1% | +308.3% | +306.2% |
RARE Depreciation And Amortization Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +96.4% | -1.2% | +147.8% | at high | +162.0% |
| 5 y | 5-year | at high | +204.6% | -1.2% | +303.7% | at high | +306.2% |
| alltime | all time | at high | >+9999.0% | -1.2% | +8401.9% | at high | >+9999.0% |
Ultragenyx Pharmaceutical Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $8.76 M(-1.2%) | $34.68 M(+4.7%) |
| Jun 2024 | - | $8.86 M(+0.2%) | $33.12 M(+11.8%) |
| Mar 2024 | - | $8.85 M(+7.6%) | $29.61 M(+13.9%) |
| Dec 2023 | $26.01 M(+42.7%) | $8.22 M(+14.3%) | $26.01 M(+14.3%) |
| Sep 2023 | - | $7.19 M(+34.1%) | $22.75 M(+12.3%) |
| Jun 2023 | - | $5.36 M(+2.4%) | $20.25 M(+4.5%) |
| Mar 2023 | - | $5.24 M(+5.6%) | $19.37 M(+6.3%) |
| Dec 2022 | $18.22 M(+37.6%) | $4.96 M(+5.6%) | $18.22 M(+8.5%) |
| Sep 2022 | - | $4.69 M(+4.8%) | $16.80 M(+9.6%) |
| Jun 2022 | - | $4.48 M(+9.6%) | $15.32 M(+9.7%) |
| Mar 2022 | - | $4.09 M(+15.7%) | $13.96 M(+5.4%) |
| Dec 2021 | $13.24 M(+8.0%) | $3.53 M(+9.9%) | $13.24 M(+3.1%) |
| Sep 2021 | - | $3.22 M(+3.1%) | $12.84 M(+1.0%) |
| Jun 2021 | - | $3.12 M(-7.3%) | $12.71 M(-0.5%) |
| Mar 2021 | - | $3.37 M(+7.5%) | $12.78 M(+4.2%) |
| Dec 2020 | $12.26 M(+43.6%) | $3.13 M(+1.3%) | $12.26 M(+8.5%) |
| Sep 2020 | - | $3.09 M(-2.9%) | $11.30 M(+9.1%) |
| Jun 2020 | - | $3.18 M(+11.6%) | $10.35 M(+11.6%) |
| Mar 2020 | - | $2.85 M(+31.5%) | $9.27 M(+8.6%) |
| Dec 2019 | $8.54 M(-56.3%) | $2.17 M(+1.1%) | $8.54 M(-8.3%) |
| Sep 2019 | - | $2.15 M(+1.9%) | $9.31 M(-19.2%) |
| Jun 2019 | - | $2.11 M(-0.6%) | $11.52 M(-25.6%) |
| Mar 2019 | - | $2.12 M(-28.0%) | $15.50 M(-20.7%) |
| Dec 2018 | $19.54 M | $2.94 M(-32.4%) | $19.54 M(+2.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $4.36 M(-28.4%) | $19.11 M(+20.6%) |
| Jun 2018 | - | $6.08 M(-1.3%) | $15.85 M(+46.4%) |
| Mar 2018 | - | $6.16 M(+145.0%) | $10.82 M(+85.8%) |
| Dec 2017 | $5.83 M(+70.1%) | $2.51 M(+129.6%) | $5.83 M(+30.4%) |
| Sep 2017 | - | $1.09 M(+3.8%) | $4.47 M(+1.5%) |
| Jun 2017 | - | $1.05 M(-9.1%) | $4.40 M(+9.0%) |
| Mar 2017 | - | $1.16 M(+0.3%) | $4.04 M(+18.0%) |
| Dec 2016 | $3.42 M(+147.4%) | $1.16 M(+12.2%) | $3.42 M(+24.6%) |
| Sep 2016 | - | $1.03 M(+49.0%) | $2.75 M(+27.4%) |
| Jun 2016 | - | $692.00 K(+27.2%) | $2.16 M(+24.9%) |
| Mar 2016 | - | $544.00 K(+13.3%) | $1.73 M(+24.8%) |
| Dec 2015 | $1.38 M(+102.3%) | $480.00 K(+8.8%) | $1.38 M(+24.0%) |
| Sep 2015 | - | $441.00 K(+68.3%) | $1.12 M(+28.4%) |
| Jun 2015 | - | $262.00 K(+30.3%) | $869.00 K(+13.2%) |
| Mar 2015 | - | $201.00 K(-5.2%) | $768.00 K(+12.3%) |
| Dec 2014 | $684.00 K(+54.1%) | $212.00 K(+9.3%) | $684.00 K(+17.1%) |
| Sep 2014 | - | $194.00 K(+20.5%) | $584.00 K(+18.0%) |
| Jun 2014 | - | $161.00 K(+37.6%) | $495.00 K(+13.3%) |
| Mar 2014 | - | $117.00 K(+4.5%) | $437.00 K(-1.6%) |
| Dec 2013 | $444.00 K(+41.9%) | $112.00 K(+6.7%) | $444.00 K(+33.7%) |
| Sep 2013 | - | $105.00 K(+1.9%) | $332.00 K(+46.3%) |
| Jun 2013 | - | $103.00 K(-16.9%) | $227.00 K(+83.1%) |
| Mar 2013 | - | $124.00 K | $124.00 K |
| Dec 2012 | $313.00 K(+820.6%) | - | - |
| Dec 2011 | $34.00 K | - | - |
FAQ
- What is Ultragenyx Pharmaceutical annual depreciation & amortization?
- What is the all time high annual D&A for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical annual D&A year-on-year change?
- What is Ultragenyx Pharmaceutical quarterly depreciation & amortization?
- What is the all time high quarterly D&A for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly D&A year-on-year change?
- What is Ultragenyx Pharmaceutical TTM depreciation & amortization?
- What is the all time high TTM D&A for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical TTM D&A year-on-year change?
What is Ultragenyx Pharmaceutical annual depreciation & amortization?
The current annual D&A of RARE is $26.01 M
What is the all time high annual D&A for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual depreciation & amortization is $26.01 M
What is Ultragenyx Pharmaceutical annual D&A year-on-year change?
Over the past year, RARE annual depreciation & amortization has changed by +$7.79 M (+42.73%)
What is Ultragenyx Pharmaceutical quarterly depreciation & amortization?
The current quarterly D&A of RARE is $8.76 M
What is the all time high quarterly D&A for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly depreciation & amortization is $8.86 M
What is Ultragenyx Pharmaceutical quarterly D&A year-on-year change?
Over the past year, RARE quarterly depreciation & amortization has changed by +$1.57 M (+21.78%)
What is Ultragenyx Pharmaceutical TTM depreciation & amortization?
The current TTM D&A of RARE is $34.68 M
What is the all time high TTM D&A for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high TTM depreciation & amortization is $34.68 M
What is Ultragenyx Pharmaceutical TTM D&A year-on-year change?
Over the past year, RARE TTM depreciation & amortization has changed by +$11.94 M (+52.48%)